Last updated on February 2019

Abatacept for the Treatment of Myositis-associated Interstitial Lung Disease

Brief description of study

A randomized, controlled pilot trial to evaluate the efficacy and safety of subcutaneous Abatacept in treating interstitial lung disease associated with the anti-synthetase syndrome.

Detailed Study Description

This is a proof of concept study to evaluate the efficacy, safety and tolerability of ABT in Syn-ILD in a multi-center randomized, placebo-controlled 6-month (24-week) pilot study.

Clinical Study Identifier: NCT03215927

Contact Investigators or Research Sites near you

Start Over

Swamy Venuturupalli, MD

Cedars-Sinai Medical Center
Beverly Hills, CA United States
  Connect »

Aryeh Fischer, MD

University of Colorado Anschutz Medical Campus
Denver, CO United States
  Connect »

Cheilonda Johnson, MD, MHS

John Hopkins Medical Center
Baltimore, MD United States
  Connect »

Paul F. Dellaripa, MD

Brigham & Women's Hospital
Boston, MA United States
  Connect »

Rohit Aggarwal, MD

University of Pittsburgh
Pittsburgh, PA United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.